(INGN) Inogen - Ratings and Ratios
Oxygen Concentrators, Respiratory Devices, Medical Accessories
INGN EPS (Earnings per Share)
INGN Revenue
Description: INGN Inogen July 15, 2025
Inogen, Inc. is a medical technology company specializing in respiratory health products, including portable oxygen concentrators for patients with chronic respiratory conditions. Their product lineup includes the Inogen One and Inogen Rove series, as well as stationary oxygen concentrators and related accessories. The company also offers rental services directly to patients, expanding its reach and revenue streams.
From a business perspective, Inogens focus on portable oxygen concentrators positions it well in the growing market for homecare and portable medical devices. The companys products are designed to enhance patient mobility and quality of life, which can lead to increased customer satisfaction and loyalty. Key performance indicators (KPIs) to watch include revenue growth, rental revenue as a percentage of total revenue, and gross margin expansion. With a market capitalization of $189.02M USD, Inogens financial health and scalability will be crucial in determining its ability to invest in research and development, expand its product offerings, and compete effectively in the healthcare equipment market.
Analyzing Inogens competitive position, we can observe that the company operates in a niche segment of the healthcare equipment industry. To assess its competitiveness, we can examine metrics such as market share, customer acquisition costs, and product innovation pipeline. Additionally, the companys return on equity (RoE) of -14.76% indicates that it is currently unprofitable, which may be a concern for investors. However, this could also be a sign of significant investment in growth initiatives. As a trading analyst, its essential to monitor Inogens progress in achieving profitability and its ability to generate cash flows to fund its operations and growth plans.
INGN Stock Overview
| Market Cap in USD | 226m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2014-02-14 |
INGN Stock Ratings
| Growth Rating | -63.8% |
| Fundamental | 27.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -20.0% |
| Analyst Rating | 3.67 of 5 |
INGN Dividends
Currently no dividends paidINGN Growth Ratios
| Growth Correlation 3m | 83.8% |
| Growth Correlation 12m | -49.9% |
| Growth Correlation 5y | -84.8% |
| CAGR 5y | -27.26% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.33 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.45 |
| Sharpe Ratio 12m | -0.74 |
| Alpha | -32.87 |
| Beta | 1.810 |
| Volatility | 68.13% |
| Current Volume | 116k |
| Average Volume 20d | 163.2k |
| Stop Loss | 8.3 (-5.4%) |
| Signal | -0.37 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-26.0m TTM) > 0 and > 6% of Revenue (6% = 20.6m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA 1.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 39.61% (prev 37.53%; Δ 2.08pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.03 (>3.0%) and CFO -8.47m > Net Income -26.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (27.0m) change vs 12m ago 14.18% (target <= -2.0% for YES) |
| Gross Margin 41.84% (prev 43.63%; Δ -1.78pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 110.6% (prev 105.7%; Δ 4.89pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.87 (EBITDA TTM -26.6m / Interest Expense TTM -9.31m) >= 6 (WARN >= 3) |
Altman Z'' -1.12
| (A) 0.44 = (Total Current Assets 203.1m - Total Current Liabilities 67.1m) / Total Assets 312.0m |
| (B) -0.52 = Retained Earnings (Balance) -163.2m / Total Assets 312.0m |
| (C) -0.12 = EBIT TTM -36.0m / Avg Total Assets 310.5m |
| (D) -1.42 = Book Value of Equity -160.2m / Total Liabilities 112.5m |
| Total Rating: -1.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.60
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -13.39% = -5.0 |
| 3. FCF Margin -4.79% = -1.80 |
| 4. Debt/Equity 0.10 = 2.50 |
| 5. Debt/Ebitda 3.18 = -2.00 |
| 6. ROIC - WACC (= -30.76)% = -12.50 |
| 7. RoE -13.77% = -2.29 |
| 8. Rev. Trend -10.74% = -0.81 |
| 9. EPS Trend 60.19% = 3.01 |
What is the price of INGN shares?
Over the past week, the price has changed by +4.78%, over one month by +4.03%, over three months by +28.97% and over the past year by -5.29%.
Is Inogen a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INGN is around 6.90 USD . This means that INGN is currently overvalued and has a potential downside of -21.32%.
Is INGN a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the INGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13 | 48.2% |
| Analysts Target Price | 13 | 48.2% |
| ValueRay Target Price | 8 | -9.2% |
INGN Fundamental Data Overview October 20, 2025
P/S = 0.6589
P/B = 1.1562
P/EG = 3.48
Beta = 1.81
Revenue TTM = 343.5m USD
EBIT TTM = -36.0m USD
EBITDA TTM = -26.6m USD
Long Term Debt = 19.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.08m USD (from shortTermDebt, last quarter)
Debt = 19.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -84.6m USD (from netDebt column, last quarter)
Enterprise Value = 122.9m USD (226.3m + Debt 19.0m - CCE 122.4m)
Interest Coverage Ratio = -3.87 (Ebit TTM -36.0m / Interest Expense TTM -9.31m)
FCF Yield = -13.39% (FCF TTM -16.5m / Enterprise Value 122.9m)
FCF Margin = -4.79% (FCF TTM -16.5m / Revenue TTM 343.5m)
Net Margin = -7.58% (Net Income TTM -26.0m / Revenue TTM 343.5m)
Gross Margin = 41.84% ((Revenue TTM 343.5m - Cost of Revenue TTM 199.7m) / Revenue TTM)
Gross Margin QoQ = 38.69% (prev 36.93%)
Tobins Q-Ratio = 0.39 (Enterprise Value 122.9m / Total Assets 312.0m)
Interest Expense / Debt = 9.26% (Interest Expense 1.76m / Debt 19.0m)
Taxrate = 3.55% (-153.0k / -4.30m)
NOPAT = -34.8m (EBIT -36.0m * (1 - 3.55%)) [loss with tax shield]
Current Ratio = 3.03 (Total Current Assets 203.1m / Total Current Liabilities 67.1m)
Debt / Equity = 0.10 (Debt 19.0m / totalStockholderEquity, last quarter 199.5m)
Debt / EBITDA = 3.18 (negative EBITDA) (Net Debt -84.6m / EBITDA -26.6m)
Debt / FCF = 5.14 (negative FCF - burning cash) (Net Debt -84.6m / FCF TTM -16.5m)
Total Stockholder Equity = 189.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.35% (Net Income -26.0m / Total Assets 312.0m)
RoE = -13.77% (Net Income TTM -26.0m / Total Stockholder Equity 189.2m)
RoCE = -17.31% (EBIT -36.0m / Capital Employed (Equity 189.2m + L.T.Debt 19.0m))
RoIC = -18.37% (negative operating profit) (NOPAT -34.8m / Invested Capital 189.2m)
WACC = 12.39% (E(226.3m)/V(245.4m) * Re(12.68%) + D(19.0m)/V(245.4m) * Rd(9.26%) * (1-Tc(0.04)))
Discount Rate = 12.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.54%
Fair Price DCF = unknown (Cash Flow -16.5m)
EPS Correlation: 60.19 | EPS CAGR: 7.09% | SUE: 0.80 | # QB: 0
Revenue Correlation: -10.74 | Revenue CAGR: -4.72% | SUE: 0.34 | # QB: 0
Additional Sources for INGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle